Cohance Lifesciences Limited confirms that all details of securities dematerialized or rematerialized during the quarter ended September 30, 2025, have been duly furnished to all stock exchanges. This confirmation is as per Regulation 74(5) of the SEBI regulations and is provided by KFin Technologies Limited, the Registrar and Share Transfer Agent. The Company ensures compliance with regulatory requirements concerning dematerialization processes.
Dematerialization Compliance
Cohance Lifesciences Limited has received confirmation regarding compliance with dematerialization regulations for Q2 FY26. The certificate, provided by KFin Technologies Limited, verifies that all necessary details regarding the dematerialization or rematerialization of securities during the quarter ended September 30, 2025, have been accurately and promptly furnished to the relevant stock exchanges.
Confirmation from Registrar
KFin Technologies Limited, the Registrar and Share Transfer Agent for Cohance Lifesciences, has issued the confirmation certificate. This certificate affirms that the company has met its obligations under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, ensuring transparency and adherence to regulatory standards in securities processing.
Regulatory Compliance
This announcement confirms Cohance Lifesciences’ commitment to maintaining high standards of corporate governance and complying with all applicable regulatory requirements related to securities transactions. The company’s proactive approach to compliance ensures the integrity and transparency of its operations.
Source: BSE
